Patient characteristics at baseline of the RA-RA group, the UA-RA group, and patients with UA who did not develop RA within 1 year
| Patient characteristics | RA-RA group (n = 62) | p Value* | UA-RA group (n = 91) | UA at presentation, no RA at 1 year (n = 238) |
|---|---|---|---|---|
| *p Value of RA-RA group versus UA-RA group. | ||||
| Results are shown as number (%) or median (interquartile range). | ||||
| Age (years) | 53 (42–72) | 0.683 | 55 (44–65) | 46 (35–58) |
| Female patients | 43 (69) | 0.492 | 58 (64) | 119 (50) |
| Duration of symptoms at first visit (days) | 130 (61–278) | 0.611 | 131 (73–230) | 81 (20–164) |
| Duration of morning stiffness (min) | 90 (45–150) | 0.035 | 60 (18–120) | 15 (0–60) |
| Number of swollen joints | 7 (5–8) | <0.001 | 4 (2–6) | 2 (1–3) |
| Modified DAS score | 3.5 (3.1–4.0) | 0.012 | 3.2 (2.7–3.7) | 2.3 (1.9–2.8) |
| Rheumatoid factor positive | 44 (71) | 0.001 | 38 (42) | 28 (12) |
| Anti-CCP antibodies | 35/59 (59) | 0.397 | 43/83 (52) | 16 (8.2) |
| ESR (mm/1st h) | 38 (20–56) | 0.695 | 31 (19–53) | 18 (9–37) |
| CRP (mg/l) | 24 (9–41) | 0.414 | 17 (8–46) | 10 (4–26) |
| HAQ score | 1.0 (0.6–1.4) | 0.184 | 0.8 (0.4–1.2) | 0.6 (0.1–1.0) |
| Erosive disease at baseline (hands and feet radiographs) | 18/60 (30) | 1.000 | 26/88 (30) | 20 (13) |
| Sharp/van der Heijde score | 1 (0–4) | 0.281 | 0 (0–3) | 0 (0–0) |